Aa
Yale Researchers- $3.5 Million to Study HCV
Yale Researchers Awarded $3.5 Million to Study Hepatitis C
Published: June 28, 2010
New Haven, Conn. Two Yale scientists have
received a $3.5 million grant from the National
Institutes of Health to study hepatitis C virus
(HCV), a deadly pathogen that attacks the liver
and afflicts about 170 million people worldwide.
Anna Marie Pyle, the William Edward Gilbert
Professor of Molecular Biophysics and
Biochemistry and an investigator for the Howard
Hughes Medical Institute, and Brett Lindenbach,
assistant professor of microbial pathogenesis,
will use the money to study the molecular underpinnings of HCV.
Current treatments for HCV are poorly tolerated
in patients and effective only in a minority. The
team hopes to dissect the critical features of
viral replication in hopes of laying the
groundwork for a new generation of therapies.
The team goal is to develop a functional
replication complex for HCV in the lab, which in
turn can be used to identify targets for new drugs.
“The success of the work will depend upon the
coordinated efforts of chemists, biochemists, and
viral geneticists,” Pyle said.
Nearly 2 percent of the U.S. population has been
infected by HCV, which can cause chronic liver
disease, cirrhosis, liver cancer and liver failure.
http://opa.yale.edu/news/article.aspx?id=7639
Published: June 28, 2010
New Haven, Conn. Two Yale scientists have
received a $3.5 million grant from the National
Institutes of Health to study hepatitis C virus
(HCV), a deadly pathogen that attacks the liver
and afflicts about 170 million people worldwide.
Anna Marie Pyle, the William Edward Gilbert
Professor of Molecular Biophysics and
Biochemistry and an investigator for the Howard
Hughes Medical Institute, and Brett Lindenbach,
assistant professor of microbial pathogenesis,
will use the money to study the molecular underpinnings of HCV.
Current treatments for HCV are poorly tolerated
in patients and effective only in a minority. The
team hopes to dissect the critical features of
viral replication in hopes of laying the
groundwork for a new generation of therapies.
The team goal is to develop a functional
replication complex for HCV in the lab, which in
turn can be used to identify targets for new drugs.
“The success of the work will depend upon the
coordinated efforts of chemists, biochemists, and
viral geneticists,” Pyle said.
Nearly 2 percent of the U.S. population has been
infected by HCV, which can cause chronic liver
disease, cirrhosis, liver cancer and liver failure.
http://opa.yale.edu/news/article.aspx?id=7639
I hope they find something that will make tx a lot faster and easier on the patient.
Thanks for the info.
Diane
Thanks for the info.
Diane
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
